Targeting the root cause of cystic fibrosis

Current Drug Targets

Volumn 16, Issue 9, 2015, Pages 937-944

  Trescott, Laura ^a   Holcomb, Joshua ^a   Spellmon, Nicholas ^a   Mcleod, Cathy ^a   Aljehane, Leala ^a   Sun, Fei ^b   Li, Chunying ^a   Yang, Zhe ^a  

^a Department of Biochemistry and Molecular Biology ^*  (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CFTR; Chloride transporter; Corrector; Cystic fibrosis; Gene therapy; Potentiator

Indexed keywords

1 (2,2 DIFLUORO 1,3 BENZODIOXOL 5 YL) N [1 (2,3 DIHYDROXYPROPYL) 6 FLUORO 2 (2 HYDROXY 1,1 DIMETHYLETHYL) 1H INDOL 5 YL]CYCLOPROPANECARBOXAMIDE; 4 PHENYLBUTYRIC ACID; CHLORIDE CHANNEL AFFECTING AGENT; CORR4A; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; KM57; KM60; LUMACAFTOR; MIGLUSTAT; RDR1; ROSCOVITINE; SILDENAFIL; THAPSIGARGIN; UNCLASSIFIED DRUG; VARDENAFIL; VELIPARIB; VRT325; CFTR PROTEIN, HUMAN;

ARTICLE; CELL MIGRATION; CHANNEL GATING; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; GENE DELETION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; MOLECULARLY TARGETED THERAPY; PROTEIN EXPRESSION; PROTEOMICS; ROOT CAUSE ANALYSIS; THERMOSTABILITY; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; ANTAGONISTS AND INHIBITORS; CELL MEMBRANE; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MUTATION; PROCEDURES; PROTEIN TRANSPORT;

CELL MEMBRANE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC THERAPY; HUMANS; MUTATION; PROTEIN TRANSPORT;

EID: 84942123199     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115999141030144247     Document Type: Article

References (112)

1. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998; 132(4): 589-95.
2. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154(5): 1229-56.
3. Schwiebert EM, Morales MM, Devidas S, Egan ME, Guggino WB. Chloride channel and chloride conductance regulator domains of CFTR, the cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci USA 1998; 95(5): 2674-9.
4. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245(4922): 1066-73.
5. Anderson MP, Gregory RJ, Thompson S, et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991; 253(5016): 202-5.
6. Ballard ST, Spadafora D. Fluid secretion by submucosal glands of the tracheobronchial airways. Respir Physiol Neurobiol 2007; 159(3): 271-7.
7. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 2008; 77: 701-26.
8. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21(4): 583-93.
9. Rowe SM, Verkman AS. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb Perspect Med 2013; 3(7). pii: a009761.
10. MacDonald KD, McKenzie KR, Zeitlin PL. Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation. Paediatr Drugs 2007; 9(1): 1-10.
11. Ntimbane T, Comte B, Mailhot G, et al. Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress. Clin Biochem Rev 2009; 30(4): 153-77.
12. Moskowitz SM, Chmiel JF, Sternen DL, et al. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet Med 2008; 10(12): 851-68.
13. MacKenzie T, Gifford AH, Sabadosa KA, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the cystic fibrosis foundation patient registry. Ann Intern Med 2014; 161(4): 233-41.
14. Bompadre SG, Sohma Y, Li M, Hwang TC. G551D and G1349D, two CF-associated mutations in the signature sequences of CFTR, exhibit distinct gating defects. J Gen Physiol 2007; 129(4): 285-98.
15. Bompadre SG, Li M, Hwang TC. Mechanism of G551D-CFTR (cystic fibrosis transmembrane conductance regulator) potentiation by a high affinity ATP analog. J Biol Chem 2008; 283(9): 5364-9.
16. Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009; 106(44): 18825-30.
17. McPhail GL, Clancy JP. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis. Drugs Today (Barc) 2013; 49(4): 253-60.
18. Eckford PD, Li C, Ramjeesingh M, Bear CE. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem 2012; 287(44): 36639-49.
19. Jih KY, Hwang TC. Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle. Proc Natl Acad Sci USA 2013; 110(11): 4404-9.
20. Kopeikin Z, Yuksek Z, Yang HY, Bompadre SG. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels. J Cyst Fibros 2014; 13(5): 508-14.
21. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363(21): 1991-2003.
22. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365(18): 1663-72.
23. De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani L. The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros 2014; 13(4): 403-9.
24. Radpour R, Gourabi H, Dizaj AV, Holzgreve W, Zhong XY. Genetic investigations of CFTR mutations in congenital absence of vas deferens, uterus, and vagina as a cause of infertility. J Androl 2008; 29(5): 506-13.
25. Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011; 108(46): 18843-8.
26. Thomas PJ, Ko YH, Pedersen PL. Altered protein folding may be the molecular basis of most cases of cystic fibrosis. FEBS Lett 1992; 312(1): 7-9.
27. Du K, Sharma M, Lukacs GL. The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests posttranslational folding of CFTR. Nat Struct Mol Biol 2005; 12(1): 17-25.
28. Denning GM, Ostedgaard LS, Welsh MJ. Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia. J Cell Biol 1992; 118(3): 551-9.
29. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358(6389): 761-4.
30. Lukacs GL, Chang XB, Bear C, et al. The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J Biol Chem 1993; 268(29): 21592-8.
31. Lewis HA, Wang C, Zhao X, et al. Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry. J Mol Biol 2010; 396(2): 406-30.
32. Protasevich I, Yang Z, Wang C, et al. Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1. Protein Sci 2010; 19(10): 1917-31.
33. Wang C, Protasevich I, Yang Z, et al. Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis. Protein Sci 2010; 19(10): 1932-47.
34. Molinski S, Eckford PD, Pasyk S, Ahmadi S, Chin S, Bear CE. Functional Rescue of F508del-CFTR Using Small Molecule Correctors. Front Pharmacol 2012; 3(160): 160.
35. Kanelis V, Hudson RP, Thibodeau PH, Thomas PJ, Forman-Kay JD. NMR evidence for differential phosphorylation-dependent interactions in WT and DeltaF508 CFTR. Embo J 2010; 29(1): 263-77.
36. Loo TW, Bartlett MC, Clarke DM. The V510D suppressor mutation stabilizes DeltaF508-CFTR at the cell surface. Biochemistry 2010; 49(30): 6352-7.
37. Thibodeau PH, Richardson JM, 3rd, Wang W, et al. The cystic fibrosis-causing mutation deltaF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J Biol Chem 2010; 285(46): 35825-35.
38. Du K, Lukacs GL. Cooperative assembly and misfolding of CFTR domains in vivo. Mol Biol Cell 2009; 20(7): 1903-15.
39. Yu W, Kim Chiaw P, Bear CE. Probing conformational rescue induced by a chemical corrector of F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutant. J Biol Chem 2011; 286(28): 24714-25.
40. Mu TW, Ong DS, Wang YJ, et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 2008; 134(5): 769-81.
41. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009; 78959-91.
42. Pedemonte N, Diena T, Caci E, et al. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations. Mol Pharmacol 2005; 68(6): 1736-46.
43. Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005; 67(5): 1797-807.
44. Loo TW, Bartlett MC, Clarke DM. Correctors promote folding of the CFTR in the endoplasmic reticulum. Biochem J 2008; 413(1): 29-36.
45. Loo TW, Bartlett MC, Clarke DM. Correctors enhance maturation of DeltaF508 CFTR by promoting interactions between the two halves of the molecule. Biochemistry 2009; 48(41): 9882-90.
46. Grove DE, Rosser MF, Ren HY, Naren AP, Cyr DM. Mechanisms for rescue of correctable folding defects in CFTRDelta F508. Mol Biol Cell 2009; 20(18): 4059-69.
47. Jurkuvenaite A, Chen L, Bartoszewski R, et al. Functional stability of rescued delta F508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells. Am J Respir Cell Mol Biol 2010; 42(3): 363-72.
48. Kim Chiaw P, Wellhauser L, Huan LJ, Ramjeesingh M, Bear CE. A chemical corrector modifies the channel function of F508del-CFTR. Mol Pharmacol 2010; 78(3): 411-8.
49. Carlile GW, Robert R, Zhang D, et al. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem 2007; 8(9): 1012-20.
50. Sampson HM, Robert R, Liao J, et al. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol 2011; 18(2): 231-42.
51. Ren HY, Grove DE, De La Rosa O, et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell 2013; 24(19): 3016-24.
52. Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 2012; 67(1): 12-8.
53. Anjos SM, Robert R, Waller D, et al. Decreasing Poly(ADPRibose) Polymerase Activity Restores DeltaF508 CFTR Trafficking. Front Pharmacol 2012; 3(165): 165.
54. Egan ME, Glockner-Pagel J, Ambrose C, et al. Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 2002; 8(5): 485-92.
55. Ca2+ level in the endoplasmic reticulum restores abnormal endogenous F508del-CFTR trafficking in airway epithelial cells. Traffic 2006; 7(5): 562-73.
56. Norez C, Vandebrouck C, Bertrand J, et al. Roscovitine is a proteostasis regulator rescuing the trafficking defect of F508del-CFTR by a CDK-independent mechanism of action. Br J Pharmacol 2014; 28(10): 12859.
57. Robert R, Carlile GW, Pavel C, et al. Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 2008; 73(2): 478-89.
58. Zaman K, Carraro S, Doherty J, et al. S-nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells. Mol Pharmacol 2006; 70(4): 1435-42.
59. Zaman K, McPherson M, Vaughan J, et al. S-nitrosoglutathione increases cystic fibrosis transmembrane regulator maturation. Biochem Biophys Res Commun 2001; 284(1): 65-70.
60. Rubenstein RC, Zeitlin PL. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol 2000; 278(2): C259-67.
61. Norez C, Antigny F, Noel S, Vandebrouck C, Becq F. A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype. Am J Respir Cell Mol Biol 2009; 41(2): 217-25.
62. Lubamba B, Lebacq J, Lebecque P, et al. Airway delivery of lowdose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med 2009; 179(11): 1022-8.
63. Dormer RL, Harris CM, Clark Z, et al. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005; 60(1): 55-9.
64. Hutt DM, Herman D, Rodrigues AP, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010; 6(1): 25-33.
65. Eckford PD, Ramjeesingh M, Molinski S, et al. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem Biol 2014; 21(5): 666-78.
66. O'Reilly R, Elphick HE. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis. Drug Des Devel Ther 2013; 7: 929-37.
67. Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Sci Transl Med 2014; 6(246): 246ra97.
68. Pettit RS, Fellner C. CFTR Modulators for the Treatment of Cystic Fibrosis. P T 2014; 39(7): 500-11.
69. Griesenbach U, Alton EW. Moving forward: cystic fibrosis gene therapy. Hum Mol Genet 2013; 22(R1): R52-8.
70. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet 2014; 15(8): 541-55.
71. Tate S, Elborn S. Progress towards gene therapy for cystic fibrosis. Expert Opin Drug Deliv 2005; 2(2): 269-80.
72. Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther 2010; 17(3): 295-304.
73. Castellani S, Conese M. Lentiviral vectors and cystic fibrosis gene therapy. Viruses 2010; 2(2): 395-412.
74. Schmidt M, Voutetakis A, Afione S, Zheng C, Mandikian D, Chiorini JA. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid-and heparan sulfate proteoglycanindependent transduction activity. J Virol 2008; 82(3): 1399-406.
75. Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther 2009; 17(2): 294-301.
76. Huser D, Gogol-Doring A, Lutter T, et al. Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome. PLoS Pathog 2010; 6(7): e1000985.
77. Flotte TR, Zeitlin PL, Reynolds TC, et al. Phase I trial of intranasal and endobronchial administration of a recombinant adenoassociated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003; 14(11): 1079-88.
78. Moss RB, Rodman D, Spencer LT, et al. Repeated adenoassociated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004; 125(2): 509-21.
79. Flotte T, Carter B, Conrad C, et al. A phase I study of an adenoassociated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7(9): 1145-59.
80. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72(2): 1438-45.
81. Zabner J, Seiler M, Walters R, et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74(8): 3852-8.
82. Halbert CL, Standaert TA, Aitken ML, Alexander IE, Russell DW, Miller AD. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 1997; 71(8): 5932-41.
83. Halbert CL, Standaert TA, Wilson CB, Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol 1998; 72(12): 9795-805.
84. Yi Y, Noh MJ, Lee KH. Current advances in retroviral gene therapy. Curr Gene Ther 2011; 11(3): 218-28.
85. Escors D, Breckpot K. Lentiviral vectors in gene therapy: their current status and future potential. Arch Immunol Ther Exp (Warsz) 2010; 58(2): 107-19.
86. Persons DA. Lentiviral vector gene therapy: effective and safe? Mol Ther 2010; 18(5): 861-2.
87. Sakuma T, Barry MA, Ikeda Y. Lentiviral vectors: basic to translational. Biochem J 2012; 443(3): 603-18.
88. Mueller C, Flotte TR. Gene therapy for cystic fibrosis. Clin Rev Allergy Immunol 2008; 35(3): 164-78.
89. Burney TJ, Davies JC. Gene therapy for the treatment of cystic fibrosis. Appl Clin Genet 2012; 5: 29-36.
90. Sinn PL, Cooney AL, Oakland M, et al. Lentiviral vector gene transfer to porcine airways. Mol Ther Nucleic Acids 2012; 1(1): e56.
91. Goldman MJ, Lee PS, Yang JS, Wilson JM. Lentiviral vectors for gene therapy of cystic fibrosis. Hum Gene Ther 1997; 8(18): 2261-8.
92. Mitomo K, Griesenbach U, Inoue M, et al. Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes. Mol Ther 2010; 18(6): 1173-82.
93. Wang G, Slepushkin V, Zabner J, et al. Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect. J Clin Invest 1999; 104(11): R55-62.
94. Kobinger GP, Weiner DJ, Yu QC, Wilson JM. Filoviruspseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 2001; 19(3): 225-30.
95. Sinn PL, Arias AC, Brogden KA, McCray PB, Jr. Lentivirus vector can be readministered to nasal epithelia without blocking immune responses. J Virol 2008; 82(21): 10684-92.
96. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364(9452): 2181-7.
97. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008; 118(9): 3132-42.
98. Fang Y, Hoh JH. Surface-directed DNA condensation in the absence of soluble multivalent cations. Nucleic Acids Res 1998; 26(2): 588-93.
99. McLachlan G, Davidson H, Holder E, et al. Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung. Gene Ther 2011; 18(10): 996-1005.
100. Eastman SJ, Lukason MJ, Tousignant JD, et al. A concentrated and stable aerosol formulation of cationic lipid:DNA complexes giving high-level gene expression in mouse lung. Hum Gene Ther 1997; 8(6): 765-73.
101. Alton EW, Boyd AC, Cheng SH, et al. A randomised, doubleblind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis. Thorax 2013; 68(11): 1075-7.
102. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008; 26(5): 549-51.
103. Griesenbach U, Alton EW. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev 2009; 61(2): 128-39.
104. Boucher RC. Status of gene therapy for cystic fibrosis lung disease. J Clin Invest 1999; 103(4): 441-5.
105. Sanders NN, De Smedt SC, Cheng SH, Demeester J. Pegylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucus. Gene Ther 2002; 9(6): 363-71.
106. Jiang C, O'Connor SP, Fang SL, et al. Efficiency of cationic lipidmediated transfection of polarized and differentiated airway epithelial cells in vitro and in vivo. Hum Gene Ther 1998; 9(11): 1531-42.
107. Stern M, Caplen NJ, Browning JE, et al. The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther 1998; 5(1): 91-8.
108. Ferrari S, Kitson C, Farley R, et al. Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium. Gene Ther 2001; 8(18): 1380-6.
109. Suk JS, Lai SK, Boylan NJ, Dawson MR, Boyle MP, Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond) 2011; 6(2): 365-75.
110. Zauner W, Kichler A, Schmidt W, Sinski A, Wagner E. Glycerol enhancement of ligand-polylysine/DNA transfection. Biotechniques 1996; 20(5): 905-13.
111. Liu X, Luo M, Guo C, et al. Analysis of adeno-associated virus progenitor cell transduction in mouse lung. Mol Ther 2009; 17(2): 285-93.
112. Mornon JP, Lehn P, Callebaut I. Molecular models of the open and closed states of the whole human CFTR protein. Cell Mol Life Sci 2009; 66(21): 3469-86.